(ACMT) Toxicology Investigators Consortium (ToxIC)
Out-of-Hospital Naloxone Administration to be Studied in New Federally-Funded Project
October 02, 2023 11:31 ET | American College of Medical Toxicology
Phoenix, AZ, Oct. 02, 2023 (GLOBE NEWSWIRE) -- In September 2023, the FDA awarded the American College of Medical Toxicology’s (ACMT) Toxicology Investigators Consortium (ToxIC) through its Broad...
CITRELOCK DUO
Acuitive Technologies Receives FDA 510(k) Clearance for CITRELOCK DUO a New Sports Medicine Fixation Device for Biceps Tenodesis and Tendon Transfer Procedures
September 27, 2023 15:50 ET | Acuitive Technologies
ALLENDALE, N.J., September 27, 2023 -- Acuitive Technologies announced the FDA 510(k) Clearance of CITRELOCK DUO Fixation Device for biceps tenodesis
Nouveau Logo communiqué de presse.JPG
Theratechnologies Submits Tesamorelin F8 Formulation sBLA for FDA Review
September 25, 2023 07:00 ET | Theratechnologies
F8 formulation intended to replace EGRIFTA SV® with simplified dosing for the treatment of excess abdominal fat in adults with HIV and lipodystrophy MONTREAL, Sept. 25, 2023 (GLOBE NEWSWIRE) --...
Nouveau Logo communiqué de presse.JPG
Theratechnologies soumet un supplément à la licence de produit biologique (sBLA) pour la formulation F8 de la tésamoréline aux fins d’examen par la FDA
September 25, 2023 07:00 ET | Theratechnologies
La formulation F8 vise à remplacer EGRIFTA SV® par une posologie simplifiée pour le traitement de l’excès de graisse abdominale chez les adultes vivant avec le VIH atteints de lipodystrophie. ...
PR - Resizing - Kaplan Fox Tagline Logo Color.jpg
INTEGRA LIFESCIENCES INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies Integra LifeSciences Investors of a Class Action Lawsuit and Upcoming Deadline
September 21, 2023 19:10 ET | Kaplan Fox & Kilsheimer LLP
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of purchasers of investors that purchased or otherwise...
NEXCELLA-Inverted-Color-2000x1500_nosubtitle_gray - rectangle.png
U.S. Food and Drug Administration Approves Orphan Drug Designation for Nexcella NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis
September 21, 2023 09:05 ET | Nexcella, Inc.
FDA Orphan Drug Designation (“ODD”) qualifies one-time treatment NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits for qualified clinical testingWaiver of the Prescription...
immix-logoNEW_gray.png
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis
September 21, 2023 08:55 ET | Immix Biopharma, Inc.
FDA Orphan Drug Designation (“ODD”) qualifies one-time treatment NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits for qualified clinical testingWaiver of the Prescription...
logo.png
Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
September 20, 2023 08:28 ET | Silo Pharma, Inc.
Pre-IND submission to FDA targeted for first quarter 2024 Silo partners with Kymanox for SPC-15 ENGLEWOOD CLIFFS, NJ, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:...
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements
September 18, 2023 16:16 ET | Sixty Degrees Pharmaceuticals
Prompted by advice from FDA regarding study design, 60P Australia Pty Ltd, a majority-owned subsidiary of 60 Degrees Pharmaceuticals, has withdrawn its IND for ACLR8-LR, a Phase IIB study of the use...
Virios Logo Blue.jpg
Virios Therapeutics Announces Termination of At-The-Market Sales Agreement
September 18, 2023 07:05 ET | Virios Therapeutics
ATLANTA, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to...